INIS
patients
100%
diseases
70%
inflammation
39%
liver
25%
risks
25%
symptoms
18%
comparative evaluations
17%
cancer
16%
levels
16%
data
15%
control
15%
reviews
14%
populations
14%
humans
11%
therapy
10%
assessments
9%
plasma
9%
interventions
9%
biological markers
9%
quality of life
8%
surgery
8%
netherlands
8%
intake
7%
concentration
7%
genes
6%
hepatitis
6%
pain
6%
glucose
6%
drugs
6%
adults
6%
diet
6%
management
6%
values
6%
mortality
5%
screening
5%
women
5%
hospitals
5%
metabolism
5%
barriers
5%
sensitivity
5%
receptors
5%
safety
5%
monitoring
5%
cost
5%
Keyphrases
Inflammatory Bowel Disease
30%
Crohn's Disease
17%
Irritable Bowel Syndrome
16%
Maastricht
15%
Type 2 Diabetes Mellitus (T2DM)
11%
Dutch
8%
Netherlands
8%
Confidence Interval
7%
Non-alcoholic Fatty Liver Disease (NAFLD)
7%
Randomized Controlled Trial
6%
Quality of Life
5%
Gastrointestinal Diseases
5%
Ulcerative Colitis
5%
Risk Factors
5%
Colorectal Cancer
5%
Medicine and Dentistry
Inflammatory Bowel Disease
22%
Irritable Bowel Syndrome
12%
Disease
10%
Maturity Onset Diabetes of the Young
10%
Quality of Life
9%
Crohn's Disease
9%
Randomized Controlled Trial
9%
Colorectal Carcinoma
8%
Nonalcoholic Fatty Liver
7%
Patient with Inflammatory Bowel Disease
6%
Systematic Review
6%
Biological Marker
5%
Colonoscopy
5%
Cohort Analysis
5%
Ulcerative Colitis
5%